Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia
Eurasian Journal of Medicine, 2011 Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome–positive ...
Murat Albayrak +6 more
doaj
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells [PDF]
, 2008 Imatinib inhibits the kinase activity of Bcr-Abl and is currently the most effective drug for treatment of chronic myeloid leukemia (CML). Imatinib also blocks c-Abl, a physiological tyrosine kinase activated by a variety of stress signals including ...
Aulitzky, W. E. +6 more
core +1 more source
Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
Acta Medica, 2003 The publication provides an up-to-date review of the significance of cytogenetic abnormalities in chronic myelogenous leukemia (CML) and the development of a promising agent with specific molecular target against tyrosine kinase, product of the BCR-ABL ...
Ladislav Chrobák, Jaroslava Voglová
doaj +1 more source
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
, 2017 Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source
Supplementary Figure 1 from PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL<sup>+</sup> Leukemia Cells <i>In Vitro</i> and <i>In Vivo</i> [PDF]
, 2023 Girija Dasmahapatra +4 more
openalex +1 more source
Indian Journal of Medical and Paediatric Oncology, 2013 Post Graduate Institute (PGI) Chandigarh is a premier institute of North India. There are approximately 70,000 admissions per year. The adult clinical hematology department sees more than 2000 new patients per year.
Pankaj Malhotra +2 more
doaj +1 more source
Chronic eosinophilic leukemia with a FIP1L1-PDGFRα fusion: case report and literature review [PDF]
, 2010 Chronic eosinophilia is habitually associated with allergic, infectious, inflammatory, neoplastic and endocrine conditions and exposure to certain drugs and toxic agents. However, eosinophilic proliferation may be primary, without identifiable causes, or
Arruda, Martha M. A. S. +3 more
core +2 more sources
Haematologica, 2008 Background Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival.
Francesca Palandri +21 more
doaj +1 more source
Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment [PDF]
, 2018 Background: Imatinib mesylate blocks the tyrosine kinase activity of KIT (CD117) and is an effective treatment for gastrointestinal stromal tumors. In multiple myeloma, KIT expression has been detected by flow cytometry in about 33% of specimens, but no ...
Dirnhofer, S. +4 more
core